Molecular Imaging News and Research

RSS

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

In the management of gliomas-or tumors that originate in the brain-precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival.

4 Dec 2012

Major advance in understanding how flu viruses replicate within infected cells

Scientists at The Scripps Research Institute (TSRI) have made a major advance in understanding how flu viruses replicate within infected cells. The researchers used cutting-edge molecular biology and electron-microscopy techniques to "see" one of influenza's essential protein complexes in unprecedented detail. The images generated in the study show flu virus proteins in the act of self-replication, highlighting the virus's vulnerabilities that are sure to be of interest to drug developers.

23 Nov 2012

Personality influences placebo response

Researchers have found that resilient, altruistic, and straightforward individuals are significantly more likely to respond to a sham painkilling or placebo injection than those who are angry and hostile.

21 Nov 2012

HHS, SJHH launch integrated Radiology and Nuclear Medicine peer review pilot project

The integrated department of diagnostic services at Hamilton Health Sciences and St. Joseph's Healthcare Hamilton announced today that it is launching a city-wide, integrated Radiology and Nuclear Medicine peer review pilot project.

17 Nov 2012

First study to measure minute changes in breast tumor connective tissue fibers

Using advanced microscopes equipped with tissue-penetrating laser light, cancer imaging experts at Johns Hopkins have developed a promising, new way to accurately analyze the distinctive patterns of ultra-thin collagen fibers in breast tumor tissue samples and to help tell if the cancer has spread.

3 Nov 2012

PET scans allow scientists to study link between caffeine and neurodegenerative disorders

Molecular imaging with positron emission tomography (PET) has enabled scientists for the first time to visualize binding sites of caffeine in the living human brain to explore possible positive and negative effects of caffeine consumption.

2 Nov 2012

Ultra-high performance SPECT systems announced by MILabs

MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices announces the release of the Plus! Systems: the U‐SPECT+ and U‐SPECT+ /CT.

29 Oct 2012

BC Cancer Agency second prestigious Vancouver institution to install MILabs Molecular Imaging System

MILabs is pleased to announce that the BC Cancer Agency, located in Vancouver, British Columbia will install a MILabs U‐SPECT/CT system to expand their current molecular oncology imaging and research capabilities. The U‐SPECT/CT is able to deliver high resolution, sensitivity and scanning speed contributing to outstanding quantification results and the ability to detect heterogeneous molecular processes in tumors.

12 Oct 2012

ImaginAb enters into neurodegeneration research collaboration agreement with Lundbeck

ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it has entered into a collaboration and commercialization agreement with H. Lundbeck A/S.

8 Oct 2012

Parametric response mapping could improve diagnosis and treatment of COPD

A new approach to lung scanning could improve the diagnosis and treatment of a lung disease that affects approximately 24 million Americans and is the country's third-highest cause of death.

8 Oct 2012

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

Determining the optimal treatment course and predicting outcomes may get easier in the future for patients with head and neck sqaumous cell carcinomas (HNSCCs) with the use of an investigational imaging agent.

2 Oct 2012

Bruker to purchase preclinical imaging product portfolio and related assets from Carestream

Carestream Health and Bruker have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream's Molecular Imaging business. Financial terms of the agreement are not being disclosed.

24 Sep 2012

F-18-FDG PET/CT may easily predict disease-free survival for invasive ductal breast cancer patients

Disease-free survival for invasive ductal breast cancer (IDC) patients may be easier to predict with the help of F-18-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans, according to research published in the September issue of The Journal of Nuclear Medicine. New data show that high maximum standard uptake value (SUVmax) of F-18-FDG in the lymph nodes prior to treatment could be an independent indicator of disease recurrence.

6 Sep 2012

Positron submits Drug Master File with FDA for production of API grade Sr-82

Positron Corporation, a leading molecular imaging healthcare company, is pleased to announce the submission of a Drug Master File (DMF), with the Federal Drug Administration (FDA), for the production of Active Pharmaceutical Ingredient (API) grade strontium-82, through its wholly owned subsidiary Manhattan Isotope Technology, LLC.

23 Aug 2012

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

9 Aug 2012

Prostate cancer cells can be killed by theranostic imaging without harming healthy cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

8 Aug 2012

New Translational Oncology Program at University of Michigan

The University of Michigan Comprehensive Cancer Center is harnessing its expertise in basic science research to speed the translation into clinical trials and new treatment opportunities for cancer patients.

6 Aug 2012

Imaging PR status may help identify tumor response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.

3 Jul 2012

Study investigates how glucose metabolism affects biochemical signals in cancer cells

Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.

27 Jun 2012

UC3M joins European research project on tuberculosis treatments

Scientists at the Carlos III University in Madrid (UC3M) are participating in a European research project designed to study tuberculosis treatments. The objective of the study is to improve diagnostic imaging technology in order to help develop new drugs to treat the disease.

22 Jun 2012